All AbMole products are for research use only, cannot be used for human consumption.
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active.
| Molecular Weight | 414.55 |
| CAS Number | 2898-95-5 |
| Solubility (25°C) | DMSO 90 mg/mL |
| Storage | 2-8°C, dry, sealed |
[1] Xintong Zhang, et al. The influence of the gut microbiota on the bioavailability of oral drugs
[4] Lili Ding, et al. Bile acid nuclear receptor FXR and digestive system diseases
| Related GPCR19/TGR5 Products |
|---|
| SB756050
SB756050 is a selective TGR5 agonist. SB756050 has the potential for type 2 diabetes treatment. |
| Deoxycholic acid sodium salt
Deoxycholic acid sodium salt activates the G protein-coupled bile acid receptor TGR5. |
| SBI-115
SBI-115 is a TGR5 (GPCR19) antagonist, it decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5. |
| INT-777
INT-777 is a potent TGR5 agonist with EC50 of 0.82 μM. |
| BAR 502
BAR502 is a dual agonist of FXR and GPBAR1 with IC50 values of 2 μM and 0.4 μM, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
